Navigation Links
Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients
Date:1/5/2009

zing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the potential regulatory approval and the benefits of administering rHuPH20 with GAMMAGARD) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a r
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
2. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
3. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
4. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
5. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
6. The American Ceramic Society releases new ACerS-NIST phase equilibria diagrams CD-ROM database
7. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
8. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
9. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
10. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
11. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Research and Markets ( ... Jain PharmaBiotech,s new report "Nanobiotechnology Applications, ... An increasing use of ... is anticipated. Nanotechnology will be applied at ... formulations for optimal delivery to diagnostic applications ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... treated and managed with the use of special anti-vascular endothelial growth factor agents ... many more patients, currently does not have a scientific protocol for the many ...
(Date:9/2/2015)... September 2, 2015 Biovista Inc. ... of the 2015 BeHEARD science challenge, a global competition ... disease researchers, access to the latest life science innovations ... repositioning and pathway analytics capability to support Steven ... in the study of Niemann-Pick Disease Type A (NPA), ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, ... developing treatments for urological and related conditions, announced today ... planned private placement convertible note financing, raising a total ... tranches totaling $3.175 million. Josh ... from this private placement are intended to be used ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
... Middleton-based Bone Care International Inc. announced on Wednesday that ... , ,Genzyme and Bone Care have signed a definitive agreement ... all-cash transaction valued at $33.00 per fully diluted ... Bone Care's shareholders at a meeting on June 30, and ...
... Perhaps its time to declare 2005 as the Year ... would say its past time. , ,At last ... headline speakers were successful women with words of advice ... included Kay Koplovitz, a South Milwaukee native who launched ...
... today announced that three Wisconsin businesses will receive funding ... Technology Matching Grant (TMG) and Technology Venture Fund (TVF) ... Technologies, Inc., and Bell Brook Labs, LLC, Meanwhile ... merger. , ,Original air date: Saturday, June 18, 2005 ...
Cached Biology Technology:Women entrepreneurs are finding ways to succeed in Wisconsin and beyond 2Women entrepreneurs are finding ways to succeed in Wisconsin and beyond 3
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions , ... entire spectrum of clinical research, is proud to announce ... company,s comprehensive SaaS-based eClinical technology platform, has led the ... first two quarters of 2015.   Q2 2015 and ... quarters measured by contract value sold in the company,s ...
(Date:8/12/2015)... Calif. , Aug. 12, 2015  Synaptics ... of human interface solutions, today announced that four ... announced Match-in-Sensor solution, have officially been named FIDO ... As part of the certification, Synaptics, Natural ID™ ... 1.0 Universal Authentication Framework (UAF) standard and are ...
(Date:8/10/2015)... The latest 364 page report from business intelligence provider ... border security market . Visiongain assesses that this ... Now: Border security is hard to achieve and harder to ... you need to know about - and more importantly, you ... this will impact your company and the border security industry ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... Center faculty have been elected to the Institute of Medicine ... Election to the Institute of Medicine (IOM) is one of ... and Columbia now has 49 members in this esteemed organization. ... Carolyn Westhoff were among the 65 new IOM members ...
... of the three most frequent malignancies in Western ... patients with early stage and local CRC approaches ... recurrence and the development of distant metastases that ... cause of CRC-related mortality. Although IL-8 ...
... publishers, has entered a publishing partnership with the Estuarine ... Appearing six times a year, the journal plays ... of estuarine and coastal ecosystems. The first issue ... partnership will be officially announced at the ERF 2007 ...
Cached Biology News:3 Columbia University Medical Center faculty elected to Institute of Medicine 2Interleukin-8, key marker for colorectal cancer treatment 2Estuarine Research Federation chooses Springer as publishing partner 2
Glutamate Receptor 5/1a...
Dual Color Mouse anti-Human Anti-Kappa FITC/CD19 PE Class: Antibody Product Group: Immunogluobulin...
... monoclonal [EP282Y] to Asparagine synthetase ... tested applications). ... to residues in the C-terminus ... Entrez GeneID: ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Biology Products: